Skip to main content
OpenTrials
Completed

NCT Number: NCT05291520

A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of VH3810109 (Also Known as GSK3810109), Administered Either Subcutaneously (SC) With rHuPH20 or Intravenously (IV), in Healthy Adult Participants

An open-label, two part study to assess the safety, tolerability, and PK of VH3810109 in healthy adult participants. Participants will receive a single SC or IV dose of VH3810109 co-administered with rHuPH20 and will be followed up for 24 weeks.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV Infections Blood-Borne Infections Communicable Diseases Genital Diseases Immune System Diseases Immunologic Deficiency Syndromes Infections Lentivirus Infections RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Urogenital Diseases Virus Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

GSK Investigational Site

Austin, Texas, 78744, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and without history of any of the conditions listed in the exclusion criteria.
  • Participants having body weight of ≥50 kilogram (kg) and <100 kg
  • Participants having a clinical laboratory profile within the normal range or must have results that do not show clinically significant abnormalities, as judged by the investigator at screening.
  • Contraceptive use by men or women participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Participants who are female at birth are eligible to participate if at least one of the following conditions applies:

Not pregnant or breastfeeding and at least one of the following conditions applies:

Is not a participant of childbearing potential (POCBP) or Is a POCBP and agree to use an acceptable contraceptive method as described in Section 10.4 from 3 weeks prior to the start of this study and during the study. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.

A POCBP must have a negative highly sensitive serum pregnancy test on Day -1, prior to the first dose of study intervention All participants in the study should be counseled on safer sexual practices including the use and benefit/risk of effective barrier methods (e.g., male condom).

The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a POCBP with an early undetected pregnancy.

  • Capable of giving written informed consent.

Exclusion criteria

  • Hypertension that is not well controlled.
  • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
  • Positive human immunodeficiency virus (HIV) antibody test.
  • Positive test result for SARS-CoV-2.
  • Evidence of hepatitis B (HB) virus infection at screening or within 3 months prior to first dose of study intervention Participants positive for Hepatitis B antigen (HBsAg) are excluded. Participants negative for anti-HBs but positive for anti-HBc (negative HBsAg status) and positive for Hepatitis B virus (HBV) DNA are excluded
  • Any history of a severe allergic reaction with generalized urticaria, angioedema or anaphylaxis within the 2 years prior to enrollment that has a reasonable risk of recurrence during the study.
  • The participant has an underlying skin disease or disorder (i.e., infection, inflammation, dermatitis, eczema, drug rash, drug allergy, psoriasis, food allergy, urticaria) or tattoos that would interfere with assessment of injection sites.
  • History of sensitivity to any of the study medications or their components or drugs of their class, or a history of drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation.
  • Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear immunoglobulin A, dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis).
  • Exposure to an experimental drug, human blood product, or vaccine (which does not have emergency, conditional, or standard market authorization) within 28 days prior to the first dose of study treatment OR plans to receive live vaccines during the study.
  • Prior receipt of licensed or investigational Monoclonal antibody (Mab).
  • Receipt of any investigational study agent within 28 days prior to first dose of study treatment
  • Prior exposure to VH3810109 or rHuPH20 in this or another clinical study.
  • Where participation in the study would result in donation of blood or blood products in excess of 500 milliliter (mL) within 56 days.
  • Exposure to more than 4 new chemical entities within 12 months prior to the first dosing day.
  • ALT ≥1.5 times the upper limit of normal (ULN).
  • Total bilirubin ≥1.5 times the ULN (isolated total bilirubin >1.5×ULN is acceptable if total bilirubin is fractionated and direct bilirubin <35%).
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
  • Corrected QT interval Fridericia's formula (QTcF)>450 millisecond (msec) for males and QTcF >470 msec for females.
  • The participant has a tattoo or other dermatological condition overlying potential injection sites that may interfere with interpretation of ISRs or administration of VH3810109.
  • Grade 4 laboratory abnormalities.
  • Any other chronic or clinically significant medical condition that in the opinion of investigator would jeopardize the safety or rights of the subject including (but not limited to): diabetes mellitus type I, chronic hepatitis; OR clinically significant forms of drug or alcohol abuse, asthma, autoimmune disease, psychiatric disorders, heart disease, or cancer.
  • Known hypersensitivity to hyaluronidase or any of the excipients in ENHANZ Drug Product (EDP)

Treatment and study plan

VH3810109

Biological

VH3810109 was administered.

rHuPH20

Biological

rHuPH20 was administered.

Primary outcomes

  1. Number of Participants With Grade 2 or Higher (>=) Adverse Events (AEs) Following SC Administration of VH3810109 (Part 1 and Part 3)

    Time frame: Up to Week 24

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AE was used for all AE severity grading, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening. This outcome measure is presenting only data for Grade 2 or more of severity.

  2. Number of Participants With Serious Adverse Events (SAEs) Following SC Administration of VH3810109 (Part 1 and Part 3)

    Time frame: Up to Week 24

    An SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect or other situations as judged by physician.

  3. Number of Participants With Injection Site Reactions (ISRs) Following VH3810109 SC Administration (Part 1 and 3)

    Time frame: Up to 7 days post-dose

    ISRs were recorded via ISR diaries and managed through investigator assessment. The participants who experienced any injection site reaction were reported.

  4. Number of Participants With Grade 2 to 4 Elevated Alanin Aminotransferase/Aspartate Aminotransferase (ALT/AST) Values Following VH3810109 SC Administration (Part 1 and 3)

    Time frame: Up to Week 24

    Liver chemistry stopping and increased monitoring criteria is analyzed using DAIDS AE Grading Table, where Grade 2 (moderate): causing greater than minimal interference with usual social and functional activities, Grade 3 (severe): causing inability to perform usual social and functional activities, Grade 4 (Potentially life threatening): causing inability to perform basic self-care functions or hospitalization indicated.

  5. Number of Participants With >= Grade 2 AEs Following IV Administration of VH3810109 (Part 2)

    Time frame: Up to Week 24

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric AE was used for all AE severity grading, where Grade 1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening. This outcome measure is presenting only data for Grade 2 or more of severity.

  6. Number of Participants With SAEs Following IV Administration of VH3810109 (Part 2)

    Time frame: Up to Week 24

    An SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect or other situations as judged by physician.

  7. Number of Participants With Grade 2 to 4 Elevated ALT/AST Values Following VH3810109 IV Administration (Part 2)

    Time frame: Up to Week 24

    Liver chemistry stopping and increased monitoring criteria is analyzed using DAIDS AE Grading Table, where Grade 2 (moderate): causing greater than minimal interference with usual social and functional activities, Grade 3 (severe): causing inability to perform usual social and functional activities, Grade 4 (Potentially life threatening): causing inability to perform basic self-care functions or hospitalization indicated.

Secondary outcomes

  1. Area Under the Plasma Concentration-time Curve (AUC) From Time Zero Extrapolated to Infinity (AUC[0-inf]) of VH3810109

    Time frame: Up to Week 24

    Blood samples were collected as assessed by protocol, at specific time points for pharmacokinetic (PK) analysis of VH3810109.

  2. AUC From Time Zero to Time t (AUC[0-t]) of VH3810109

    Time frame: Up to Week 24

    Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.

  3. Maximum Observed Concentration (Cmax) of VH3810109

    Time frame: Up to Week 24

    Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.

  4. Time of Maximum Observed Concentration (Tmax) of VH3810109

    Time frame: Up to Week 24

    Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.

  5. Apparent Terminal Phase Half-life (t1/2) of VH3810109

    Time frame: Up to Week 24

    Blood samples were collected as assessed by protocol, at specific time points for PK analysis of VH3810109.

  6. Score Recorded for "Acceptance of ISRs", Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)

    Time frame: At Day 2 and Day 7

    The PIN questionnaire measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial. Scores range from 1 to 5; questions are phrased to ensure that 1: most favorable perception of vaccination, and 5: most unfavorable. Score of a dimension is calculated as mean of all items with dimension. Higher scores represent worse perception of injection.

  7. Number of Participants Reporting Pain, Using Perception of Injection (PIN) Questionnaire (Part 1 and 3)

    Time frame: At Day 2 and Day 7

    The PIN questionnaire measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial.

    Scores range from 1 to 5; the scores are defined as following: 1=not at all bothered, 2=a little bothered, 3=moderately bothered, 4=very bothered, 5=extremely bothered; questions are phrased to ensure that 1: most favorable perception of vaccination, and 5: most unfavorable. Score of a dimension is calculated as mean of all items with dimension. Higher scores represent worse perception of injection.

  8. Number of Participants Reporting Being Bothered or Affected by the Pain and Local Reactions Based on the PIN Questionaire (Part 1 and 3)

    Time frame: At Day 2 and Day 7

    The PIN questionnaire measure contains 21 items: pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside clinical trial.

    Scores range from 1 to 5; the scores are defind as following: 1=totaly acceptable, 2=very acceptable, 3=moderately acceptable, 4=a little acceptable, 5=not at all acceptable; questions are phrased to ensure that 1: most favorable perception of vaccination, and 5: most unfavorable. Score of a dimension is calculated as mean of all items with dimension. Higher scores represent worse perception of injection.

  9. Score Reported for Post-injection Pain Assessment Using Numeric Rating Scale (NRS) Following VH3810109 SC Administration (Part 1 and 3)

    Time frame: At Day 1, Day 2 and Day 7

    Post-injection assessment of pain was measured based on NRS which is a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst possible pain).

  10. Scores Reported for Post-injection Pain Assessment Using Numeric Rating Scale (NRS) Following VH3810109 IV Administration (Part 2)

    Time frame: At Day 1, Day 2 and Day 7

    Post-injection assessment of pain was measured based on NRS which is a 11-point numerical rating scale ranging from 0 (no pain) to 10 (worst possible pain).

  11. Number of ISRs Events Overall and by Grade (Part 1 and 3)

    Time frame: Up to day 14

    ISRs were recorded via ISR diaries and managed through investigator assessment. Severity of injection site reactions was analyzed using DAIDS AE Grading Table. The severity was categorized into grades as following: Grade 1 (mild): causing no or minimal interference with usual social and functional activities, Grade 2 (moderate): causing greater than minimal interference with usual social and functional activities, Grade 3 (severe): causing inability to perform usual social and functional activities, Grade 4 (Potentially life threatening): causing inability to perform basic self-care functions or hospitalization indicated, Grade 5 (death). Higher grade indicates more severe condition.

  12. The Overall Duration of ISRs, Expressed in Days

    Time frame: From Day 1 up to Day 14

    ISRs will be recorded via ISR diaries and managed through investigator assessment.

  13. Change From Baseline in Platelets, White Blood Cells (WBC), Neutrophils, Lymphocytes, Monocytes, Eosinophils and Basophils

    Time frame: From Baseline (Day -1) up to Week 24

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

  14. Change From Baseline in Hematocrit

    Time frame: From Baseline (Day -1) up to Week 24

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

  15. Change From Baseline in Hemoglobin, Albumin and Total Protein

    Time frame: From Baseline (Day -1) up to Week 24

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

  16. Change From Baseline in Red Blood Cell Count (RBC)

    Time frame: From Baseline (Day -1) up to Week 24

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

  17. Change From Baseline in Mean Corpuscle Volume (MCV)

    Time frame: From Baseline (Day -1) up to Week 24

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

  18. Change From Baseline in Mean Corpuscle Hemoglobin (MCH)

    Time frame: From Baseline (Day -1) up to Week 24

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

  19. Change From Baseline in Glucose (Fasting), Blood Urea Nitrogen (BUN), Creatinine, Direct Bilirubin and Total Bilirubin

    Time frame: From Baseline (Day -1) up to Week 24

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

  20. Change From Baseline in Sodium, Potassium, Calcium, Chloride and Carbon Dioxide

    Time frame: From Baseline (Day -1) up to Week 24

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

  21. Change From Baseline in ALT, AST and Alkaline Phosphatase (ALP)

    Time frame: From Baseline (Day -1) up to Week 24

    Blood samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109.

  22. Number of Participants With Worst Case Urinalysis at Post-baseline Compared With Baseline

    Time frame: Day 14 compared with baseline (Day -1)

    Urine samples were collected as assessed by protocol, at specific time points for laboratory analysis of VH3810109. At baseline and post-baseline, worst case urinalysis data was determined by comparing the resulted values of the urinalysis for each participant to the normal rage. This endpoint evaluates the changes from baseline for the worst case urinalysis.

  23. Change From Baseline in PR Interval, QRS Interval, QT Interval, and QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF)

    Time frame: From Baseline (Day -1) up to Week 24

    ECG values were collected as assessed by protocol, at the indicated time points.

  24. Change From Baseline in Temperature

    Time frame: From Baseline (Day -1) up to Week 24

    Temperature was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.

  25. Change From Baseline in Pulse Rate

    Time frame: From Baseline (Day -1) up to Week 24

    Pulse rate was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.

  26. Change From Baseline in Respiratory Rate

    Time frame: From Baseline (Day -1) up to Week 24

    Respiratory rate was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.

  27. Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)

    Time frame: From Baseline (Day -1) up to Week 24

    Blood pressure was measured at the indicated time points, in a supine position after the participant has been at rest for at least 5 minutes in a quiet setting without distractions.

Sponsors and collaborators

Lead sponsor

ViiV Healthcare

Industry

Registry information

Official study title

A Phase 1, Open-Label, Single-Dose Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, GSK3810109, Administered Either Subcutaneously or Intravenously With Recombinant Human Hyaluronidase PH20 (rHuPH20) to Healthy Adults

Acronym: SPAN

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Mar 22, 2022
Registry last updated
Sep 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.